Very much, it is not (a historic day)..
Read my quick research on the AYUSH Ashwagandha registered trials mentioned by @drharshvardhan.

Here is why AYUSH COVID-19 protocol is too primitive & the bill should wait until there is a systematic review on published data. Contd.. https://twitter.com/drharshvardhan/status/1313500150204035072

Ashwagandha (Withania somnifera): There are a total of 7 clinical trials registered on CTRI website against COVID-19
3/7 are on post-COVID-19 + patients, and
4/7 are prophylactic studies to boost immunity in healthy people.

In the 3 trials using Ashwagandha,
researchers only included asymptomatic or mild cases of age 20-60 yr (reduced risk)

One clinical trial even went so far as to include only:
1 Uncomplicated cases taking allopathy
2 Where ventilator support is not required &
3 No comorbidities

In the same 3 trials using Ashwagandha for COVID+,
the EXCLUSION criterion was somewhat more dramatic,
1 Cases with comorbidities (low risk)
2 Age 60+ people (low risk)
3 If the patient develops any side effects (Isnt Ayurveda free of side effects?)
Contd..

4 If symptoms aggravate to moderate or severe during study.
5 Moderate & Severe patients
6 That develop respiratory failure or require ventilation
7 Any other condition, which as per the investigator would jeopardize the outcome of the trial.

So exactly what are they testing??

The exclusion criterion no. 4 & 7 make the studies completely unethical (& useless) as it specifically excludes patients in whom the drug doesn't work.
Moreover, with inclusion criteria of selecting only mild-no symptom patients, the study is data dredging/ p-hacking at its worst